SUZANNAH K. SUNDBY Partner, Canady + Lortz LLP 1050 30 th Street, NW Washington, DC 20007 State of Affairs in 101 Patent Land AIPLA Corporate Practice.

Slides:



Advertisements
Similar presentations
In re Bilski Federal Circuit (2008) (en banc) Decided: October 30, 2008 A very SMALL decision on a very BIG issue!
Advertisements

ITU WORKSHOP ON STANDARDS AND INTELLECTUAL PROPERTY RIGHTS (IPR) ISSUES Session 5: Software copyright issues Dirk Weiler, Chairman of ETSI General Assembly.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association CLS BANK: PATENT ELIGIBILITY UNDER SECTION 101 JIPA/AIPLA Meeting By Joseph A. Calvaruso.
Chapter 5: Mutual Assent
Second level — Third level Fourth level »Fifth level CLS Bank And Its Aftermath Presented By: Joseph A. Calvaruso Orrick, Herrington & Sutcliffe LLP ©
Q UINCY COLLEGE Paralegal Studies Program Paralegal Studies Program Litigation & Procedure Introduction To Litigation Litigation & Procedure Introduction.
Recent Cases on Patentable Subject Matter and Patent Exhaustion Mojdeh Bahar, J.D., M.A. Chief, Cancer Branch Office of Technology Transfer National Institutes.
Orlando, Florida | Mayo v. Prometheus by:Jon M. Gibbs Lowndes, Drosdick, Doster, Kantor and Reed PA.
Diagnostics: Patent Eligibility and the Industry Perspective
What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.
INTRODUCTION TO PATENT RIGHTS The Business of Intellectual Property
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
© 2011 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Patenting Methods of Medical Treatment in the United States AIPPI 2011 Forum/ExCo Peter.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
11 Post-Bilski Case Law Update Remy Yucel Director, Central Reexamination Unit.
Mayo v. Prometheus Decided March 20, 2012 Roberte Makowski, Ph.D., J.D. Hans Sauer, Ph.D., J.D.
AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College.
Establishing Foreign Law Source: Gerhard Dannemann: Establishing Foreign Law in a German Court, German Law Archive,
Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts | | fax | wolfgreenfield.com Recent Developments.
John B. Pegram Fish & Richardson P.C. New York “Divided” or “Joint” Infringement.
Librarians and the Unauthorized Practice of Law.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo Senior Legal Advisor Office of Patent Legal Administration Biotechnology/Chemical/Pharmaceutical.
LIMITED LIABILITY PARTNERSHIPS A Review of Legal Issues By John E. Rogers, of Burns, Fitzpatrick, Rogers & Schwartz 0.
2015 AIPLA IP Practice in Europe Committee June, 2015 Phil Swain Foley Hoag LLP Boston, MA - USA The Effect of Alice v CLS Bank on patent subject matter.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association UPDATE ON SUBJECT MATTER ELIGIBILITY, CLS BANK AND ITS AFTERMATH Joseph A. Calvaruso.
1 1 AIPLA Firm Logo American Intellectual Property Law Association Myriad Guidance for Biotechnology and Chemical Practice Joerg-Uwe Szipl Griffin and.
Medical Device Partnership: USPTO Interim Eligibility Guidance Michael Cygan, USPTO June 2, 2015.
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
Theresa Stadheim-Schwegman Lundberg & Woessner, PA Sharon Israel – Mayer Brown LLP June 2015 Lexmark v. Impression Products - patent exhaustion issues.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Patentable Subject Matter and Design Patents,Trademarks, and Copyrights David L. Hecht, J.D., M.B.A, B.S.E.E.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association PENDING U.S. SUPREME COURT CASES JPAA Meeting Tokyo, Japan Joseph A. Calvaruso Orrick,
The Supreme Court at Work
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
Biotechnology/Chemical/Pharmaceutical Customer Partnership: Recent Examiner Training and Developments Under 35 USC § 101 Drew Hirshfeld Deputy Commissioner.
Patent Prosecution Luncheon March White House Patent Reform: Executive Actions Draft rule to ensure patent owners accurately record and regularly.
Public Policy Considerations and Patent Eligible Subject Matter Relating to Diagnostic Inventions Disclaimer: Any views expressed here are offered in order.
Judicially Created Diversity in Patent Law Norman Siebrasse Professor of Law University of New Brunswick, Canada.
Subject Matter Patentability for Bioinformatics Patent Applications Principles & Practice Gregory L. Maurer Klarquist Sparkman, LLP AIPLA Spring Meeting.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
© 2011 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is the property of Barnes & Thornburg LLP which may not be reproduced,
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
11 PATENT LAW Randy Canis CLASS 15 Case Law Update.
The American Court System Chapter 3. Why Study Law And Court System? Manager Needs Understanding Managers Involved In Court Cases As Party As Witness.
1 1 AIPLA Firm Logo American Intellectual Property Law Association Update on US Caselaw, including Myriad and Hamilton Beach Joerg-Uwe Szipl Griffin and.
1 1 AIPLA Firm Logo American Intellectual Property Law Association The Presumption of Patent Validity in the U.S. Tom Engellenner AIPLA Presentation to.
Summary Judgment and Summary Adjudication LA 310.
AMP v. US PTO: Section 101 and DNA Sequence Patents Joshua D. Sarnoff DePaul U. College of Law 25 E. Jackson Blvd. Chicago, IL,
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with §101 – A Prosecution Perspective for Biotechnology Derived Innovation.
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with A Prosecution Perspective on the Protection of Computer Implemented.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
Prosecution Group Luncheon Patent October PTO News Backlog of applications continues to decrease –623,000 now, decreasing about 5,000/ month –Expected.
Patenting Software in the USA ISYM540 Topic 4 – Societal Issues Len Smith July 2009.
The Trial Civ Lit I: Unit 9. 2 Preparing for Trial.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
Intro to the Appellate Process When a party loses at trial they have the right to appeal the decision. An appeal is always about whether the law was correctly.
Jody Blanke, Professor Computer Information Systems and Law 1.
What did Enfish V Microsoft do? Dr. Sinai Yarus©
Restoring the Patent System: Countering Supreme Court Attacks on What Can be Patented David Kappos Robert Armitage Bruce Sunstein Denise Kettelberger,
The Challenge of Biotech Patent Eligibility in the United States:
Alexandria, Virginia July 21, 2014
The Spanish doctrine of equivalents after alimta®
The Mayo-Alice Dogma and Paths to Eligibility for BioPharma
Recent USPTO Developments on Subject Matter Eligibility
Protection of Computer-Related Invention in Japan
Protection of AI Inventions in Japan
Subject Matter Eligibility
A tutorial and update on patentable subject matter
Presentation transcript:

SUZANNAH K. SUNDBY Partner, Canady + Lortz LLP th Street, NW Washington, DC State of Affairs in 101 Patent Land AIPLA Corporate Practice Group Luncheon Meeting December 15, 2015

The Current State of Affairs is Grim 2

The Mayo/Alice Two-Part Test First, determine whether the claims are directed to a law of nature, natural phenomenon, or an abstract idea. Second, determine whether the elements of the claim both individually and as an ordered combination transform the nature of the claim in to a patent-eligible application.  Markedly different  Significantly more 3

USPTO Application of “Directed To” “Directed to” means that a judicial exception is recited in the claim. For nature-based products, “directed to” apparently includes products that have no naturally occurring counterpart.  Interim Guidance requires comparing with the naturally occurring counterpart in its natural state to determine if it has a markedly different structure, function, and/or other property, and if there is no naturally occurring counterpart, the comparison is to the closest naturally occurring counterpart. For abstract ideas, “directed to” apparently means anything that can be performed mentally even if the claim requires the use of a particular device. 4

USPTO Application of “Marked Difference” and “Significantly More” “Marked difference” seems to be a question of nonobviousness – unexpected results, and different in kind, rather than degree “Significantly more” seems to be more than the judicial exception itself  Excludes steps and elements that are well-understood, routine, or conventional. What is something that is “well-understood, routine, or conventional”?  Something completely novel  Never used or done before for any reason 5

USPTO is Erring on the Side of Stupidity Ex parte Shideler, Application 11/779,876 (PTAB 2015) Claim 12 is to a method of playing a story based card game in which the cards are placed at predetermined locations. Claims 17 and 18 require the use of a game board and player tokens, respectively. PTAB says: “The use of cards having indicia specific to the subject matter of a game is well-known, well- understood, routine and conventional in the field … tokens and a game board [are also] conventional in the field.”  Therefore, claims are ineligible. 6

Ariosa v. Sequenom Parties agreed that the claims at issue do not claim cell- free fetal DNA itself. Claims directed to methods of using the cffDNA, and require tangible process steps. “The method ends with paternally inherited cffDNA, which is also a natural phenomenon. The method therefore begins and ends with a natural phenomenon. Thus, the claims are directed to matter that is naturally occurring.” The tangible process steps were considered well- understood, routine, and conventional.  Note the process steps were never before performed on cffDNA. CAFC says ineligible, en banc rehearing denied. 7

Federal Circuit Has No Backbone Blame SCOTUS and Mayo  “[I]t is unsound to have a rule that takes inventions of this nature out of the realm of patent-eligibility on grounds that they only claim a natural phenomenon plus conventional steps, or that they claim abstract concepts. But I agree that the panel did not err in its conclusion that under Supreme Court precedent it had no option other than to affirm the district court.”  Concurrence by Lourie joined by Moore  “Mayo has unambiguously announced a generally applicable test for determining subject-matter eligibility under § 101 with respect to laws of nature, and we are bound to follow it. We cannot confine Mayo to its facts or otherwise cabin a clear statement from the Supreme Court.”  Concurrence by Dyk 8

Except Newman “I agree with my colleagues that this case is wrongly decided. However, I do not share their view that this incorrect decision is required by Supreme Court precedent. The facts of this case diverge significantly from [from Mayo]. “ “Precedent does not require that all discoveries of natural phenomena or their application in new ways or for new uses are ineligible for patenting; the Court has cautioned against such generalizations. Such caution takes hold for the case at bar.” 9

Stupidity Means Mayo USPTO’s position on “well-understood, routine, or conventional” is arguably correct in view of Mayo as evidenced by Lourie and Dyk’s concurrences in denying an en banc rehearing in Ariosa. 10

But Does it Really? In his concurrence, Dyk states: “And it is undisputed that before this invention, the amplification and detection of cffDNA from maternal blood, and use of these methods for prenatal diagnoses, were not routine and conventional. But applying Mayo, we are unfortunately obliged to divorce the additional steps from the asserted natural phenomenon to arrive at a conclusion that they add nothing innovative to the process.” SCOTUS stated in Mayo that: “Indeed, scientists routinely measured metabolites as part of their investigations into the relationships between metabolite levels and efficacy and toxicity of thiopurine compounds. '623 patent, col. 8, ll , id., at 10. Thus, this step tells doctors to engage in well- understood, routine, conventional activity previously engaged in by scientists who work in the field.” 11

Easy Way to Clear Court Dockets Helmet mounted tracking ineligible despite motion sensors physically mounted on two different objects.  “The plain language of Claim 1 describes generic, fungible inertial sensors that admittedly have already gained “widespread acceptance” in the field of motion tracking. Like the computer elements in Alice, these inertial trackers, when considered as an ordered combination in the claimed system, add nothing transformative to the patent. Although the concept of tracking the motion of a moving object relative to a moving reference frame may have been novel and nonobvious, the claimed system does nothing to ground this abstract idea in a specific way. The claims allow for the application of the navigation equation in almost endless environments, and are not limited to a fighter jet and a pilot’s helmet.”  Granted defendants motion for judgment on the pleadings. Thales Visionix v. USA and Elbit Systems (Ct. Fed. Clm. 2015). 12

The Future State of Affairs is Grim 13

Disclaimer These materials and views expressed today reflect only the personal views of the author and do not necessarily represent the views of other members and clients of the author’s organizations. These materials are public information and have been prepared solely for educational purposes to contribute to the understanding of U.S. intellectual property law. While every attempt was made to ensure that these materials are accurate, errors or omissions may be contained therein, for which any liability is disclaimed. These materials and views are not a source of legal advice and do not establish any form of attorney-client relationship with the author and Canady + Lortz LLP. 14

Thank You! Suzannah K. Sundby, Esq. Canady + Lortz LLP th Street, NW Washington, DC T: F: Suzannah practices all aspects of intellectual property law including patent preparation, and prosecution, licensing, opinion work, strategic planning, and client counseling relating to diverse technologies including biochemistry, molecular biology, pharmaceuticals, microfluidics, diagnostics, medical devices, and nanotechnology. 15

Extra Slides 16

Ex parte Shideler 12. A method of playing a story based card game associated with a predetermined story and having a series of locations associated with the predetermined story and wherein the game includes a preset number of sequential rounds, the card game comprising: a plurality of sets of location cards, one set of location cards for each of the plurality of locations associated with an aspect of the predetermined story, each set of location cards including one card for each round of the game, wherein each round includes at least one correct location card for that round, wherein each correct location card for each round includes indicia indicating that it is the correct card for that round and including a continuation of the story, whereby a series of correct locations cards for the rounds of the game combine to form a story summary, the method comprising the steps of having the players selectively choose a location card for each round and having the players repeat the selection process until one player can identify all of the correct location cards in the series of correct location cards. 17

Thales Visionix v. USA and Elbit Systems 1. A system for tracking the motion of an object relative to a moving reference frame, comprising:  a first inertial sensor mounted on the tracked object;  a second inertial sensor mounted on the moving reference frame; and  an element adapted to receive signals from said first and second inertial sensors and configured to determine an orientation of the object relative to the moving reference frame based on the signals received from the first and second inertial sensors. 18